• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    VectivBio Holding, Greenhill, Atea Pharmaceuticals And Other Big Stocks Moving Higher On Monday

    5/22/23 10:31:37 AM ET
    $AVIR
    $AZUL
    $CINT
    $DNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Air Freight/Delivery Services
    Consumer Discretionary
    Get the next $AVIR alert in real time by email

    U.S. stocks traded higher, with the Dow Jones gaining around 50 points on Friday. Here are some big stocks recording gains in today’s session.

    • Greenhill & Co., Inc. (NYSE:GHL) shares rose 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share.
    • VectivBio Holding AG (NASDAQ:VECT) gained 38.5% to $16.20 after Ironwood Pharmaceuticals announced it would acquire the company for $17 per share.
    • Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) shares surged 33.5% to $4.9375. Tang Capital Partners, Concentra sent acquisition proposal to Atea Pharmaceuticals with terms to acquire all of its outstanding common stock.
    • Outlook Therapeutics, Inc. (NASDAQ:OTLK) climbed 17.2% to $1.57.
    • Krystal Biotech, Inc. (NASDAQ:KRYS) gained 15.7% to $111.18. Krystal Biotech announced a $160 million private placement equity financing.
    • Upstart Holdings, Inc. (NASDAQ:UPST) gained 14.6% to $26.41.
    • Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) gained 14.5% to $7.36.
    • CI&T Inc (NASDAQ:CINT) rose 14.2% to $4.0750. CI&T recently reported Q1 financial results.
    • Azul S.A. (NYSE:AZUL) gained 13.6% to $9.55. B of A Securities upgraded Azul from Underperform to Neutral and raised the price target from $6.9 to $11.
    • IonQ, Inc. (NASDAQ:IONQ) climbed 13% to $10.04.
    • Kodiak Sciences Inc. (NASDAQ:KOD) gained 12.2% to $6.63. Kodiak Sciences recently reported a year-over-year increase in first-quarter EPS.
    • Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) jumped 11.5% to $1.4250.
    • Mondee Holdings, Inc. (NASDAQ:MOND) rose 11.5% to $10.91. Mondee recently posted upbeat quarterly results.
    • Solid Power, Inc. (NASDAQ:SLDP) jumped 10.7% to $2.10.
    • MultiPlan Corporation (NYSE:MPLN) gained 10.4% to $1.1150.
    • Twist Bioscience Corporation (NASDAQ:TWST) surged 10.4% to $14.39. Twist Bioscience launched portfolio of RNA sequencing tools.
    • Zai Lab Limited (NASDAQ:ZLAB) jumped 8.6% to $34.22.
    • TrueBlue, Inc. (NYSE:TBI) gained 8.6% to $17.42. BMO Capital upgraded TrueBlue from Market Perform to Outperform and raised the price target from $18 to $20.
    • Twilio Inc. (NYSE:TWLO) climbed 8.1% to $55.38. Twilio recently reported first-quarter results and issued weak top-line guidance.
    • NIO Inc. (NYSE:NIO) climbed 7.7% to $8.69 after the Chinese government announced interest rates would remain unchanged.

     

    Read More: US Stocks Mixed; Nordic American Tankers Posts Upbeat Results

    Get the next $AVIR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVIR
    $AZUL
    $CINT
    $DNA

    CompanyDatePrice TargetRatingAnalyst
    Krystal Biotech Inc.
    $KRYS
    3/27/2026Peer Perform
    Wolfe Research
    Solid Power Inc.
    $SLDP
    3/16/2026$7.00Buy
    H.C. Wainwright
    Upstart Holdings Inc.
    $UPST
    3/16/2026$43.00Neutral → Buy
    BTIG Research
    NIO Inc.
    $NIO
    3/13/2026$6.80Hold → Buy
    HSBC Securities
    NIO Inc.
    $NIO
    3/11/2026$6.60Neutral → Buy
    Nomura
    Twilio Inc.
    $TWLO
    3/2/2026Hold → Buy
    TD Cowen
    Upstart Holdings Inc.
    $UPST
    2/17/2026$30.00Sell → Neutral
    Compass Point
    Upstart Holdings Inc.
    $UPST
    2/13/2026$20.00Mkt Perform → Mkt Underperform
    Citizens
    More analyst ratings

    $AVIR
    $AZUL
    $CINT
    $DNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Edmondson Frazor Titus Iii

    4 - Zai Lab Ltd (0001704292) (Issuer)

    4/3/26 5:58:53 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Smiley Joshua L

    4 - Zai Lab Ltd (0001704292) (Issuer)

    4/3/26 5:59:18 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Amado Rafael

    4 - Zai Lab Ltd (0001704292) (Issuer)

    4/3/26 5:57:35 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVIR
    $AZUL
    $CINT
    $DNA
    SEC Filings

    View All

    SEC Form DEFA14A filed by Krystal Biotech Inc.

    DEFA14A - Krystal Biotech, Inc. (0001711279) (Filer)

    4/3/26 4:32:43 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Krystal Biotech Inc.

    DEF 14A - Krystal Biotech, Inc. (0001711279) (Filer)

    4/3/26 4:31:33 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Zai Lab Limited

    144 - Zai Lab Ltd (0001704292) (Subject)

    4/2/26 4:59:22 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVIR
    $AZUL
    $CINT
    $DNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Teuber William J Jr bought $115,155 worth of shares (3,000 units at $38.38), increasing direct ownership by 47% to 9,413 units (SEC Form 4)

    4 - IonQ, Inc. (0001824920) (Issuer)

    2/27/26 9:55:03 PM ET
    $IONQ
    EDP Services
    Technology

    CEO and President Owen Taryn R bought $77,316 worth of shares (20,400 units at $3.79), increasing direct ownership by 3% to 791,807 units (SEC Form 4)

    4 - TrueBlue, Inc. (0000768899) (Issuer)

    2/26/26 4:54:32 PM ET
    $TBI
    Professional Services
    Consumer Discretionary

    EVP, Chief Legal Officer Ferencz Garrett bought $25,270 worth of shares (7,000 units at $3.61), increasing direct ownership by 3% to 234,135 units (SEC Form 4)

    4 - TrueBlue, Inc. (0000768899) (Issuer)

    2/26/26 2:05:23 PM ET
    $TBI
    Professional Services
    Consumer Discretionary

    $AVIR
    $AZUL
    $CINT
    $DNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 19, 2023 - FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

    For Immediate Release: May 19, 2023 Today, the U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.  “Vyjuvek is the first FDA-approved gene therapy treatment for DEB, a

    5/19/23 1:48:20 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    March 26, 2021 - Coronavirus (COVID-19) Update: March 26, 2021

    For Immediate Release: March 26, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On March 23, 2021, the FDA issued an emergency use authorization (EUA) to the Twist Bioscience Corporation for their SARS-CoV-2 NGS Assay. The SARS-CoV-2 NGS Assay is a next-generation sequencing (NGS) based test for the identification of SARS-CoV-2 RNA from respirato

    3/26/21 3:51:09 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVIR
    $AZUL
    $CINT
    $DNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cheche Group Reports Second Half and Full Year 2025 Unaudited Financial Results

    BEIJING, April 2, 2026 /PRNewswire/ -- Cheche Group Inc. (NASDAQ:CCG) ("Cheche," "the Company" or "we"), China's leading auto insurance technology platform, today announced its unaudited financial results for the second half and full year ended December 31, 2025. Key Business HighlightsPartnerships with New Energy Vehicle (NEV) companies(1) reached 16 in the second half 2025 and led to 1.2 million policies with corresponding written premium of RMB3.7 billion (US$532.0 million), representing an increase of 61.8% and 63.9%, respectively, compared to the prior-year period. Embedded policies and corresponding written premium for the full year 2025 reached 2.0 million and RMB6.3 billion (US$902.1

    4/2/26 6:00:00 AM ET
    $CCG
    $NIO
    Specialty Insurers
    Finance
    Auto Manufacturing
    Industrials

    Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

    - Collaboration with Amgen to explore the clinical potential of Zai Lab's DLL3-targeting ADC, zocilurtatug pelitecan, in combination with Amgen's IMDELLTRA® - Amgen to sponsor and lead global Phase 1b study; Zai Lab to retain full ownership of zocilurtatug pelitecan Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ:AMGN) to evaluate Zai Lab's investigational delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci, formerly ZL-1310), in combination with Amgen's IMDELLTRA® (tarlatamab-dlle), a DLL3-targeting Bispecific T-cell Engager (BiTE®) therapy in patients with extensive-st

    4/1/26 7:30:00 AM ET
    $AMGN
    $ZLAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    NIO Inc. Provides March and First Quarter 2026 Delivery Update

    35,486 vehicles were delivered in March 2026, increasing by 136.0% year-over-year83,465 vehicles were delivered in the three months ended March 2026, increasing by 98.3% year-over-yearCumulative deliveries reached 1,081,057 as of March 31, 2026   SHANGHAI, April 01, 2026 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE:NIO, HKEX: 9866, SGX: NIO)) ("NIO" or the "Company"), a pioneer and a leading company in the global smart electric vehicle market, today announced its March and first quarter 2026 delivery results. The Company delivered 35,486 vehicles in March 2026, representing an increase of 136.0% year-over-year. The deliveries consisted of 22,490 vehicles from the Company's premium smart electric v

    4/1/26 5:30:00 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    $AVIR
    $AZUL
    $CINT
    $DNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Krystal Biotech

    Wolfe Research initiated coverage of Krystal Biotech with a rating of Peer Perform

    3/27/26 8:50:59 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Solid Power with a new price target

    H.C. Wainwright initiated coverage of Solid Power with a rating of Buy and set a new price target of $7.00

    3/16/26 8:42:58 AM ET
    $SLDP
    Industrial Machinery/Components
    Miscellaneous

    Upstart upgraded by BTIG Research with a new price target

    BTIG Research upgraded Upstart from Neutral to Buy and set a new price target of $43.00

    3/16/26 8:34:06 AM ET
    $UPST
    Finance: Consumer Services
    Finance

    $AVIR
    $AZUL
    $CINT
    $DNA
    Financials

    Live finance-specific insights

    View All

    Cheche Group Reports Second Half and Full Year 2025 Unaudited Financial Results

    BEIJING, April 2, 2026 /PRNewswire/ -- Cheche Group Inc. (NASDAQ:CCG) ("Cheche," "the Company" or "we"), China's leading auto insurance technology platform, today announced its unaudited financial results for the second half and full year ended December 31, 2025. Key Business HighlightsPartnerships with New Energy Vehicle (NEV) companies(1) reached 16 in the second half 2025 and led to 1.2 million policies with corresponding written premium of RMB3.7 billion (US$532.0 million), representing an increase of 61.8% and 63.9%, respectively, compared to the prior-year period. Embedded policies and corresponding written premium for the full year 2025 reached 2.0 million and RMB6.3 billion (US$902.1

    4/2/26 6:00:00 AM ET
    $CCG
    $NIO
    Specialty Insurers
    Finance
    Auto Manufacturing
    Industrials

    NIO Inc. Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results

    Quarterly Adjusted Profit From Operations (non-GAAP) Reached RMB1,251.3 Million (US$178.9 Million)i Quarterly Total Revenues Reached RMB34,650.2 Million (US$4,954.9 Million)iQuarterly Vehicle Deliveries Were 124,807 Units Full Year Total Revenues Reached RMB87,487.5 Million (US$12,510.5 Million) Full Year Vehicle Deliveries Were 326,028 Units SHANGHAI, China, March 10, 2026 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE:NIO, HKEX: 9866, SGX: NIO)) ("NIO" or the "Company"), a pioneer and a leading company in the global smart electric vehicle market, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025. Operating Highlights for the Fourth Quarter

    3/10/26 6:30:00 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026 Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care Expanded Antiviral Pipeline with New Hepatitis E Virus (HEV) Program; Lead Product Candidate AT-587 Expected

    3/5/26 4:05:00 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVIR
    $AZUL
    $CINT
    $DNA
    Leadership Updates

    Live Leadership Updates

    View All

    Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

    Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion's Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role. As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a rare and differentiated perspective of how to translate scientific promise into successful clinical programs. Her experience spans executive roles in biotech and large pharma, with p

    3/25/26 7:59:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twilio Appoints Doug Robinson to Board of Directors

    Twilio (NYSE:TWLO), the customer engagement platform that drives real-time, personalized experiences for today's leading brands, today announced that Doug Robinson has been appointed to the Twilio Board of Directors, effective immediately. Robinson is a seasoned executive, previously holding the position of Co-President of Workday. He brings decades of experience in scaling global organizations, specifically overseeing GTM efforts, allowing him to provide a unique perspective as Twilio focuses on expanding its platform and retaining customers. "Doug has a proven track record of scaling global organizations with immense rigor and discipline," said Khozema Shipchandler, CEO of Twilio. "Duri

    3/24/26 4:15:00 PM ET
    $TWLO
    Computer Software: Prepackaged Software
    Technology

    Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

    Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (NASDAQ:KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth from FDA approval in 2023 to $389 million in annual sales in 2025 Ms. McDonough to lead Palvella's Market Access and Patient Services organizations, advancing payer engagement, patient support, specialty distribution, and access strategy for the Company's QTORIN™ programs targeting serious, rare skin diseases and vascular malformations WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or "the Company") (Nasdaq: PVLA), a clinical-stage biopharmaceut

    3/23/26 7:30:00 AM ET
    $KRYS
    $PVLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AVIR
    $AZUL
    $CINT
    $DNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Azul S.A.

    SC 13G - AZUL SA (0001432364) (Subject)

    12/6/24 4:26:59 PM ET
    $AZUL
    Air Freight/Delivery Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

    SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

    11/15/24 10:34:54 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

    SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)

    11/14/24 9:00:58 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care